Seagen

NCT06377566

CollaboratorPhase 2Recruiting202471 people22 Apr 2024clinicaltrials.gov

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

CollaboratorPhase 2Active, not recruiting202325 people28 Jun 2023clinicaltrials.gov

NCT05911295

Phase 3Active, not recruiting2023412 people22 Jun 2023clinicaltrials.gov

NCT04700124

CollaboratorPhase 3Active, not recruiting2021808 people7 Jan 2021clinicaltrials.gov

NCT04685616

CollaboratorPhase 3Recruiting20221,042 people28 Dec 2020clinicaltrials.gov

NCT04569032

Phase 2Completed202082 people29 Sept 2020clinicaltrials.gov

NCT04389632

Phase 1Recruiting20201,006 people15 May 2020clinicaltrials.gov

NCT04223856

CollaboratorPhase 3Active, not recruiting2020886 people10 Jan 2020clinicaltrials.gov

NCT03826602

Phase 1Completed201918 people1 Feb 2019clinicaltrials.gov

NCT03755804

CollaboratorPhase 2Active, not recruiting2018232 people28 Nov 2018clinicaltrials.gov

NCT03646123

Phase 2Terminated2019255 people24 Aug 2018clinicaltrials.gov

NCT03582033

Phase 1Terminated201883 people10 Jul 2018clinicaltrials.gov

NCT03288545

CollaboratorPhase 1/2Terminated2017348 people20 Sept 2017clinicaltrials.gov

NCT02855359

Phase 2Terminated201624 people4 Aug 2016clinicaltrials.gov

NCT02734771

CollaboratorPhase 2Active, not recruiting201624 people12 Apr 2016clinicaltrials.gov

NCT02505269

CollaboratorPhase 2Completed201534 people22 Jul 2015clinicaltrials.gov

NCT01925612

Phase 2Terminated201387 people20 Aug 2013clinicaltrials.gov

NCT01920932

CollaboratorPhase 2Active, not recruiting201377 people12 Aug 2013clinicaltrials.gov

NCT01777152

Phase 3Completed2013452 people28 Jan 2013clinicaltrials.gov

NCT01712490

CollaboratorPhase 3Completed20121,334 people23 Oct 2012clinicaltrials.gov